Recommendations Developed for Lymphangioleiomyomatosis

Share this content:
Recommendations Developed for Lymphangioleiomyomatosis
Recommendations Developed for Lymphangioleiomyomatosis

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- In a Clinical Practice Guideline published in the American Journal of Respiratory and Critical Care Medicine, evidence-based recommendations are presented for the diagnosis and management of lymphangioleiomyomatosis (LAM).

Francis X. McCormack, M.D., from the University of Cincinnati, and colleagues performed systematic reviews to summarize the evidence relating to diagnosis and treatment of LAM. Evidence-based recommendations were formulated, written, and graded.

The authors considered the panel's confidence in the estimated effects, the balance of benefits versus harms and burdens of treatment, patient values and preferences, cost, and feasibility, and formulated recommendations for or against specific interventions. Recommendations included treatment with sirolimus rather than observation for patients with LAM with abnormal/declining lung function, and treatment with sirolimus before invasive management for selected patients with LAM with problematic chylous effusions. Vascular endothelial growth factor D testing was recommended to establish LAM diagnosis before consideration of diagnostic lung biopsy. Doxycycline and hormonal therapy were not recommended for LAM treatment.

"Evidence-based recommendations for the diagnosis and treatment of patients with LAM are provided," the authors write. "Frequent reassessment and updating will be needed."

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »